Homogenous Good Outcome in a Heterogeneous Group of Tumors: An Institutional Series of Outcomes of Superficial Soft Tissue Sarcomas

Table 3

Literature review of treatment and outcomes for S-STS.

Series		Histologies	Location	Median size (range)	T-stage	Margin status	% receiving RT	Median follow-up (range)	LR rate	5-year OS
Rydholm et al., 1991 (Sweden) [19]	129	LMS, 18%	EX, 85%	4.3 cm (1–16 cm)	5 cm, 58%	Wide, 58.1%	8.5%	NR	24.8%	80%
		MFH, 46%	T, 15%		5 cm, 38%	Close, 41.9%
		LPS, 10%	H/N, 0%		Unknown, 4%
		AS, 0%	Other, 0%
		Other, 26%
Brooks et al., 1998 (USA) [14]	215	LMS, 16%	EX, 100%	NR	5 cm, 75%	R0, 91.6%	25%	45 months (2 d–151 months)	14%	79%
		MFH, 43%	T, 0%		5 cm, 25%	R1, 8.4%
		LPS, 18%	H/N, 0%
		AS, 3%	Other, 0%
		Other, 20%
Cany et al., 1999 (France) [15]	105	LMS, 20%	EX, 56.1%	3 cm (1–15 cm)	5 cm, 65.7%	Wide, 85.4%	52.8%	111.9 months (19.2–321.9 months)	10.5%	75%
		MFH, 39%	T, 27.7%		5 cm, 34.3%	Close, 14.6%
		LPS, 3%	H/N, 16.2%
		AS, 5%	Other, 0%
		Other^2, 33%
Salas et al., 2009 (France) [16]	367	LMS, 22.3%	EX, 55.0%	NR	5 cm, 76.3%	Wide, 76.3%	35.4%	74.2 months	23.4%	80.9%
		MFH^1, 9.0%	T, 35.4%		5 cm, 21%	Close, 21.2%
		AS, 14.4%	H/N, 8.0%		Unknown, 2.7%	Unknown, 2.5%
		Other^2, 54.3%	Other, 1.6%
Tsukushi et al., 2012 (Japan) [20]	105	LMS, 7.6%	EX, 73.3%	NR	5 cm, 45.7%	R0, 95.2%	4.8%	NR	8.0%	95.3%
		MFH, 24.8%	T, 26.7%		5 cm, 54.3%	R1, 4.8%
		LPS, 19.0%
		Other, 48.6%
Francescutti et al., 2015 (USA) [present study]	103	LMS, 35.9%	EX, 51.5%	3 cm (0.15–14 cm)	5 cm, 79.0%	Wide, 75.2%	21.3%	34.2 months (2.3–176.0 months)	8.7%	93.2%
		MFH, 15.5%	T, 38.8%		5 cm, 21.0%	Close, 18.8%
		LPS, 7.8%	H/N, 7.8%
		AS, 5.8%	Other, 1.9%
		Other, 35.0%
Total	1024

Myxofibrosarcoma in this series.
Dermatofibrosarcoma protuberans (DFSP) in this series.
LMS, leiomyosarcoma; MFH, malignant fibrous histiocytoma; LPS, liposarcoma; AS, angiosarcoma; EX, upper or lower extremity; T, superficial trunk; H/N, head and neck; NR, not reported.